BR9603429A - Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado - Google Patents

Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado

Info

Publication number
BR9603429A
BR9603429A BR9603429A BR9603429A BR9603429A BR 9603429 A BR9603429 A BR 9603429A BR 9603429 A BR9603429 A BR 9603429A BR 9603429 A BR9603429 A BR 9603429A BR 9603429 A BR9603429 A BR 9603429A
Authority
BR
Brazil
Prior art keywords
derivative
estra
pharmaceutical composition
preparation process
substituted phenyl
Prior art date
Application number
BR9603429A
Other languages
English (en)
Inventor
Ronald Gebhard
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9603429(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9603429A publication Critical patent/BR9603429A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9603429A 1995-08-17 1996-08-14 Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado BR9603429A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202229 1995-08-17

Publications (1)

Publication Number Publication Date
BR9603429A true BR9603429A (pt) 1998-05-12

Family

ID=8220570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9603429A BR9603429A (pt) 1995-08-17 1996-08-14 Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado

Country Status (26)

Country Link
US (1) US6011025A (pt)
EP (1) EP0763541B1 (pt)
JP (1) JP3977462B2 (pt)
KR (1) KR100445376B1 (pt)
CN (1) CN1129602C (pt)
AR (1) AR003982A1 (pt)
AT (1) ATE182596T1 (pt)
AU (1) AU711369B2 (pt)
BR (1) BR9603429A (pt)
CA (1) CA2182771C (pt)
CZ (1) CZ287740B6 (pt)
DE (1) DE69603425T2 (pt)
DK (1) DK0763541T3 (pt)
ES (1) ES2137625T3 (pt)
GR (1) GR3031116T3 (pt)
HK (1) HK1002010A1 (pt)
HU (1) HU229023B1 (pt)
IL (1) IL118974A (pt)
NO (1) NO306257B1 (pt)
NZ (1) NZ299181A (pt)
PL (1) PL183468B1 (pt)
RU (1) RU2135514C1 (pt)
SG (1) SG52834A1 (pt)
TR (1) TR199600664A2 (pt)
TW (1) TW464654B (pt)
ZA (1) ZA966555B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
EP1726307A3 (en) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
IL135469A0 (en) 1997-10-06 2001-05-20 Univ Leland Stanford Junior Methods for treating psychosis associated with glucocorticoid related dysfunction
ATE317699T1 (de) 1998-05-15 2006-03-15 Univ Leland Stanford Junior Glucocorticoid receptor antagonisten zur behandlung von demenz
DE60004377T2 (de) * 1999-04-06 2004-06-09 Akzo Nobel N.V. Oral wirksame 7-alpha-alkyl androgene
CA2438480C (en) * 2001-02-14 2011-05-03 Abbott Laboratories Glucocorticoid receptor modulators
EP1285927A3 (de) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
CA2463446C (en) * 2001-10-26 2010-02-23 Akzo Nobel N.V. Use of (11.beta., 17.beta.)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
EP1581234A4 (en) * 2002-11-05 2007-09-12 Corcept Therapeutics Inc METHODS FOR TREATING MIGRAINE
EP1599208A4 (en) * 2003-02-04 2007-09-12 Corcept Therapeutics Inc ANTIGLUCOCORTICOIDES FOR THE TREATMENT OF POSTPARTAL PSYCHOSIS
TW200820977A (en) 2006-08-08 2008-05-16 Organon Nv Use of glucocorticoid receptor antagonists for treatment of infectious conditions
US8658128B2 (en) * 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP2701744A4 (en) * 2011-03-23 2014-08-20 Pop Test Cortisol Llc COMBINATION THERAPY
EP2712317B1 (en) 2011-03-31 2018-09-19 Pop Test Oncology LLC Prevention of infection
WO2012145258A1 (en) * 2011-04-18 2012-10-26 Pop Test Cortisol Llc Hair loss treatment
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
WO2015187289A1 (en) 2014-06-03 2015-12-10 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
AU2016226451B2 (en) * 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
AU2016235298B2 (en) * 2015-03-23 2021-03-11 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
MX2017011885A (es) 2015-03-30 2018-02-19 Corcept Therapeutics Inc Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.
US9598459B2 (en) * 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
EP3400233A4 (en) * 2015-08-03 2020-02-26 Pop Test Oncology LLC PHARMACEUTICAL COMPOSITIONS AND METHODS
US9829495B2 (en) 2015-08-13 2017-11-28 Corcept Therapeutics, Inc. Method for differentially diagnosing ACTH-dependent Cushing's syndrome
CN108699102A (zh) * 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3394079A4 (en) * 2015-12-23 2019-08-21 Oric Pharmaceuticals, Inc. INHIBITORS OF GLUCOCORTICOIDREZEPTORS
MX2018008849A (es) 2016-01-19 2019-01-31 Corcept Therapeutics Inc Diagnostico diferencial de sindrome de cushing ectopico.
ES2867853T3 (es) 2016-10-07 2021-10-21 Oric Pharmaceuticals Inc Inhibidor del receptor de glucocorticoides
WO2018236749A2 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. METHODS OF TREATING NEURO-EPITHELIAL TUMORS USING GLUCOCORTICOID RECEPTOR SELECTIVE MODULATORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
WO1995004536A1 (en) * 1993-08-04 1995-02-16 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
CA2149496C (en) * 1994-05-19 2006-12-19 Ronald Gebhard 11,21-bisphenyl-19-norpregnane derivatives

Also Published As

Publication number Publication date
CA2182771A1 (en) 1997-02-18
CN1129602C (zh) 2003-12-03
CN1147520A (zh) 1997-04-16
CZ238696A3 (en) 1997-05-14
CA2182771C (en) 2007-04-24
PL183468B1 (pl) 2002-06-28
RU2135514C1 (ru) 1999-08-27
TW464654B (en) 2001-11-21
ATE182596T1 (de) 1999-08-15
MX9603476A (es) 1997-07-31
TR199600664A2 (tr) 1997-03-21
PL315733A1 (en) 1997-03-03
DE69603425D1 (de) 1999-09-02
NO963427D0 (no) 1996-08-16
HU9602269D0 (en) 1996-10-28
HUP9602269A3 (en) 1997-12-29
KR100445376B1 (ko) 2004-11-08
KR970010784A (ko) 1997-03-27
NO963427L (no) 1997-02-18
DE69603425T2 (de) 2000-01-20
AU6211996A (en) 1997-02-20
DK0763541T3 (da) 2000-02-28
HK1002010A1 (en) 1998-07-24
US6011025A (en) 2000-01-04
GR3031116T3 (en) 1999-12-31
ZA966555B (en) 1997-02-19
AU711369B2 (en) 1999-10-14
HUP9602269A2 (en) 1997-04-28
CZ287740B6 (en) 2001-01-17
IL118974A (en) 2001-09-13
SG52834A1 (en) 1998-09-28
NO306257B1 (no) 1999-10-11
JP3977462B2 (ja) 2007-09-19
EP0763541A1 (en) 1997-03-19
IL118974A0 (en) 1996-10-31
EP0763541B1 (en) 1999-07-28
JPH09104696A (ja) 1997-04-22
AR003982A1 (es) 1998-09-30
ES2137625T3 (es) 1999-12-16
HU229023B1 (en) 2013-07-29
NZ299181A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
BR9603429A (pt) Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
BR9609738A (pt) Composições para aplicação de droga para estabilidade melhorada de esteróides
EE200000319A (et) hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon
CY2013003I2 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
EE03263B1 (et) Erütromütsiini derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja vaheühendid
FI955913A (fi) Uudet erytromysiinijohdannaiset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
FI955235A0 (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
BR9707501A (pt) Composto composição farmacêutica e uso do composto
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
BR9711311B1 (pt) derivado de 1,2,3,4-tetrahidroquinolina, composiÇço farmaceutica, uso de um derivado de 1,2,3,4-tetrahidroquinolina, e, processo para a preparaÇço de compostos.
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
BR9707808A (pt) Composto composição farmacêutica e uso do composto
BR9712058B1 (pt) formulações para uso de ivermectina, processo para sua preparação e uso.
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE9800145A (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
BR9612413A (pt) Composto uso do mesmo e composição farmacêutica
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI973229A (fi) Uusi farmaseuttinen koostumus

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: N.V. ORGANON (NL)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V.

B25A Requested transfer of rights approved

Free format text: TRANSFERIDO DE: N.V. ORGANON

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.